The rodent blood Pig-a assay has been undergoing international validation for use as an in vivo hematopoietic cell gene mutation assay, and given the promising results an Organization for Economic Co-operation and Development (OECD) Test Guideline is currently under development. Enthusiasm for the assay stems in part from its alignment with 3Rs principles permitting combination with other genotoxicity endpoint(s) and integration into repeat-dose toxicology studies. One logistical requirement and experimental design limitation has been that blood samples required antibody labeling and flow cytometric analysis within one week of collection. In the current report, we describe the performance of freeze-thaw reagents that enable storage and subsequent labeling and analysis of rat blood samples for at least seven months. Data generated from three laboratories are presented that demonstrate rat erythrocyte recoveries in the range of 80-90%. Despite some loss of erythrocytes, Pearson coefficients and Bland-Altman analyses based on fresh blood vs. frozen/thawed matched pairs indicate that mutant cell and reticulocyte frequencies are not significantly affected, as the measurements are highly correlated and exhibit low bias. Collectively, these data support the effectiveness and suitability of a freeze-thaw procedure that endows the assay with several new advantageous characteristics that include: flexibility in scheduling personnel/instrumentation; reliability when shipping samples from in-life facilities to analytical sites; 3Rs-friendly, as blood from positive control animals can be stored frozen to serve as analytical controls; and ability to defer a decision to generate Pig-a data until more toxicological information becomes available on a test substance. Environ. Mol. Mutagen. 60:47-55, 2019.
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INTRODUCTION
Lack of one or more glycosylphosphatidylinositol (GPI)-anchored proteins on hematopoietic cells' outer membrane can be used as a reporter of phosphatidylinositol glycan-class A (Pig-a) gene mutation (Araten et al., 1999; Chen et al., 2001; Bryce et al., 2008; Miura et al., 2008; Rondelli et al., 2013) . For instance, in the case of rat erythrocytes, fluorochrome-conjugated antibodies against the GPI-anchored antigen CD59, together with flow cytometric analysis, are used to score the incidence of nonfluorescent mutant cells relative to fluorescent wild-type cells. DNA-sequencing results clearly support the use of the GPI anchor-deficient phenotype as a reliable reporter of Pig-a gene mutation (Kimoto et al., 2011; Dobrovolsky et al., 2015; Nicklas et al., 2015; Revollo et al., 2015 Revollo et al., , 2016 Krüger et al., 2016; Bemis et al., 2017) .
The low blood volume requirement, compatibility with commonly used rodent strains, and the relatively low cost of these Pig-a studies relative to other in vivo mutagenesis systems makes this assay attractive for studies concerned with hematopoietic cell mutation (Dobrovolsky et al., 2010; Schuler et al., 2011) . Furthermore, work with reference genotoxicants indicates that flow cytometric analysis is capable of detecting treatment-related increases in the frequencies of mutant phenotype cells using acute and subchronic exposure schedules (Dertinger et al., 2012; Kimoto et al., 2014 Kimoto et al., , 2016 . This flexibility endows the assay with 3Rs-friendly characteristics, as it facilitates integrated studies that include other genotoxicity and/or toxicity endpoints Bhalli et al., 2013; Kimoto et al., 2014; Stankowski et al., 2015) .
Given these attractive characteristics, the in vivo Pig-a assay has been the subject of international validation efforts comprised of industry, regulatory agencies, and academia, with important organizational support provided by the Health and Environmental Science Institute's Genetic Toxicology Technical Committee (HESI-GTTC), the International Workshop on Genotoxicity Testing (IWGT) (Schuler et al., 2011; Gollapudi et al., 2015) , the Japan Health Sciences Foundation (Kimoto et al., 2013) , and the Japanese Environmental Mutagen Society's (JEMS) Mammalian Mutagenesis Study Group (MMS) (Kimoto et al., 2016) . Among the findings of inter-and intra-laboratory validation work is that with proper training, reproducibility and repeatability of erythrocyte-based Pig-a assays are demonstrably high (Dertinger et al., 2011a; Kimoto et al., 2013 and Godin-Ethier et al., 2015; Gollapudi et al., 2015; Johnson et al., 2016; Raschke et al., 2016) .
While assay characteristics described above have generated a high level of enthusiasm for the assay's potential, one challenging feature is that samples have required labeling and analysis within about one week of collection (Gollapudi et al., 2015) . To enhance the flexibility surrounding Pig-a analyses, we sought to develop a procedure for storing rodent blood samples for extended periods of time before flow cytometric processing occurs. The optimized method entails combining whole blood samples with a freezing solution, mixing, and transferring the resulting cell suspensions to an ultracold freezer, without the need for liquid nitrogen or special apparatus for controlling the freezing rate. The proof-of-principle inter-laboratory Pig-a data reported herein are discussed in terms of their implications for several logistical and experimental design considerations. Rat experiments were conducted with the oversight and approval of the University of Rochester's Institutional Animal Care and Use Committee (IACUC). Two male Sprague-Dawley rats were purchased from Charles River Laboratories, Wilmington, MA. Rodents were allowed to acclimate for approximately one week, and their age at the start of treatment was 12 weeks. Water and food were available ad libitum throughout the acclimation and experimental periods. The ENU dosing solution was prepared fresh each day in PBS that was adjusted to pH 6.0 prior to solubilization. For each of three consecutive days of administration, rats were treated via oral gavage with either 0 or 20 mg ENU/kg/day.
MATERIALS AND METHODS

Reagents
Approximately 10 mL blood were collected 14 weeks after treatment via cardiac puncture following CO 2 overdose. Each sample was immediately placed into a K 2 -EDTA tube (Becton Dickinson, cat. no. 366643) and maintained on ice or in a 4 C refrigerator until further processing occurred, as described below.
Study 2: iuvo-Litron
The in-life portion of this study was conducted with the oversight of and approval of iuvo Bioscience's IACUC. Twenty male and 20 female Sprague-Dawley rats were purchased from Charles River Laboratories, Wilmington, MA. Rodents were allowed to acclimate for approximately one week, and their age at the start of treatment was 6-7 weeks. Water and food were available ad libitum throughout the acclimation and experimental periods. The ENU dosing solutions were prepared fresh each day in PBS that was adjusted to pH 6.0 prior to solubilization. For each of three consecutive days of administration, rats were treated via oral gavage with either 0, 5, 10, or 20 mg ENU/kg/day; n = 5 males and 5 females per treatment group. Approximately 0.5 mL blood was collected 21 days after the last treatment via cardiac puncture. Each sample was immediately placed into a 2 mL K 2 -EDTA tube (Becton Dickinson, Franklin Lakes, NJ) and maintained on ice until further processing occurred, as described below.
Study 3: Covance
This study was conducted with the oversight and approval of Covance Laboratories' IACUC. Twenty-four male Sprague-Dawley rats were purchased from Charles River Laboratories, Raleigh, NC. Rodents were allowed to acclimate for approximately one week, and their age at the start of treatment was 7 weeks. Water and food were available ad libitum throughout the acclimation and experimental periods. The carboplatin dosing solutions were prepared fresh each day in 0.9% saline. For each of three consecutive days of administration, rats were treated via intravenous (i.v.) administration with 0, 7.5, 15 or 30 mg/kg/day of carboplatin (n = 6 per treatment group) with dosing volume of 10 mL/kg body weight.
Approximately, 200 μL blood was collected 29 days after start of treatment via jugular vein. Each sample was immediately placed into a 2 mL K 2 -EDTA tube (Becton Dickinson, cat. no. 367842) and maintained on ice until further processing occurred, as described below.
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Allocating Samples Across Storage/Transportation Conditions
Study 1: Litron
For Pig-a analyses that occurred on fresh (i.e., never-frozen) blood samples, 80 μL of each blood sample was transferred to tubes containing 100 μL kit-supplied anti-coagulant solution where they remained at room temperature for less than 2 hr until leukodepletion was performed, as described below. Note that for each of the two rat blood samples, three 80 μL aliquots were transferred in this manner in order to accomplish three technical replicate Pig-a analyses. Frozen blood was also divided into multiple aliquots in order to provide three technical replicate readings at each of three different analysis dates (i.e., following 0.5, 1, and 3 months of frozen storage). Each of the aliquots consisted of 100 μL K 2 -EDTA blood that was combined with 0.5 mL kit-supplied freezing solution in a Simport-brand cryotube (cat. no. T310-2). Gentle mixing occurred by pipetting the cells up and down several times. After allowing the suspensions to incubate in the freezing solution for 5 min at room temperature, they were transferred to a − 80 C freezer for various amounts of time before thawing and further processing occurred, as described below.
Study 2: iuvo-Litron
Approximately 100 μL of anticoagulated blood were added to 0.5 mL kitsupplied freezing solution in a Corning-brand cryotube. Samples were processed in this manner several times to facilitate multiple analyses over time. The resulting cell suspensions were maintained at ambient temperature for ≤10 minutes prior to placing them in a freezer set to maintain −65 C. The remaining volume of anticoagulated whole blood was couriered same day to Litron Laboratories for fresh (never frozen) Pig-a analysis.
After 1 month, frozen blood samples from each female rat were placed on dry ice and shipped overnight to Bristol-Myers Squibb (New Brunswick, NJ). As needed, dry ice was replenished and the samples were shipped overnight to Litron Laboratories for analysis. Shipment was conducted in this manner to simulate typical shipping conditions within the continental United States. After 6 months, a full set of samples (male and female rats) was placed on dry ice and shipped overnight to Charles River Laboratories (Skokie, IL) and then to Litron in the same fashion. Upon receipt at Litron, samples were transferred to a −85 C freezer for an additional 1 month, meaning the samples were stored in a frozen state for a total of 7 months. Samples were processed for flow cytometry-based Pig-a mutant cell frequency determinations as described below.
Study 3: Covance
For Pig-a analyses that occurred on fresh blood samples, 80 μL of each blood sample was transferred to tubes containing 100 μL kit-supplied anticoagulant solution where they remained at room temperature for less than 30 min until leukodepletion was performed, as described below. For Pig-a analyses that occurred on frozen/thawed blood samples, 100 μL of each blood sample was transferred to Simport-brand cryotubes (cat. no. T310-2A) that contained 0.5 mL kit-supplied freezing solution. Gentle mixing was performed by pipetting cells up and down several times. After allowing the suspensions to incubate in the freezing solution for 5 min at room temperature, they were transferred to a −80 C freezer for six months before thawing and further processing occurred, as described below.
Pig-a Mutation: Sample Preparation, Data Acquisition
CD59-, and RET frequencies were determined for fresh blood samples as well as frozen/thawed blood samples via immunomagnetic depletion of wild-type erythrocytes and flow cytometric analysis according to instructions provided in the MutaFlow Kit manual (available at www.litronlabs.com), and as described previously (Dertinger et al., 2011b (Dertinger et al., , 2012 . In the case of fresh blood samples, the entire 80 μL blood + 100 μL anti-coagulant suspension was layered on top of Lympholyte ® -Mammal in the normal fashion, and cells continued to be processed according to the MutaFlow Kit instructions.
In the case of frozen samples, vials were removed from freezers, thawed in a 37 C water bath, and resulting cell suspensions were transferred to 15-mL polypropylene centrifuge tubes. Thawing Solution A was added, 150 μL per tube, and mixing occurred via brief low-speed vortexing. Samples were maintained at room temperature, undisturbed, for 5 min, at which point 750 μL Thawing Solution B were added to each tube and briefly vortexed. Thawing Solution B was added two more times at 5 min intervals: 900 μL then 4.8 mL per tube. At this point, thawed cells were collected via centrifugation (5 min at 1100 × g, swinging bucket rotor). Supernatants were aspirated, cell pellets were loosened with tapping, and 100 μL kit-supplied anti-coagulant solution were added to each specimen. The contents of each tube were layered on top of Lympholyte ® -Mammal solution and cells were processed according to the standard MutaFlow Kit instruction manual from that point forward.
An Instrument Calibration Standard was generated on each day of data acquisition. These samples contained approximately 50% wild-type and 50% mutant-mimic erythrocytes, and as described previously, provided a means to rationally and consistently define the location of CD59-negative cells . A BD FACSCanto™ II flow cytometer running FACSDiva™ v6.1.2 software was used for data acquisition and analysis.
Calculations, Statistical Analyses
The formulas used to calculate RBC CD59-, RET , and RET frequencies based on pre-and post-immunomagnetic column data are described in the MutaFlow instruction manual (www.litronlabs.com). All of these calculations were performed in Excel Office X for Mac ® (Microsoft, Seattle, WA). Note that all raw data and calculated RBC CD59-, RET CD59-, RET frequencies, as well as cell recovery results, will be made available at the Pig-a In Vivo Gene Mutation Database: https://www.pharmacy.umaryland. edu/centers/cersi-files.
Study 1: Litron
Pig-a mutant cell frequencies generated from the analysis of blood samples from two rats (vehicle-vs. ENU-treated), three technical replicates per rat, and four storage conditions (fresh, and stored frozen for 0.5, 1 and 3 months), were evaluated via two-way ANOVA (JMP ® , v12.0.1). These analyses considered the effect of treatment, storage condition, and treatment × storage condition interaction on RBC CD59-and RET CD59-frequencies (alpha 0.05). Note that mutant cell frequencies were cube root transformed in order to meet the homogeneity of variance assumption (Levene's test, alpha 0.05).
Study 2 and 3: iuvo-Litron, and Covance
RBC
CD59-, RET CD59-, and RET frequencies generated from fresh, never-frozen blood samples were compared to frequencies observed in corresponding, frozen blood samples. To facilitate quantitative comparisons, the matched pairs were evaluated in two manners: Pearson coefficients (R 2 ) provided a measure of correlation, and Bland-Altman plots facilitated assessment of agreement and bias (Altman and Bland, 1983) .
RESULTS
Reagents and Protocol Optimization
Early experiments were directed at identifying freezing and thawing solutions that provided for a simple and Environmental and Molecular Mutagenesis. DOI 10.1002/em effective method for preserving blood samples for later Pig-a analysis. Among the cryopreservation reagents considered, we evaluated hydroxyethyl starch, polyethylene glycol of various molecular weights, glycerol, dimethyl sulfoxide, fetal bovine serum, trehalose, and various combinations. Solutions used during thawing/ recovery included various buffered salt solutions, as well as carbohydrate solutions of various osmolarities. Initial experiments focused on the recovery of erythrocytes, which during our early work tended to be on the order of 1-10%. It was only after a considerable amount of systematic optimization occurred that three proprietary solutions were developed that consistently provided ≥80% recovery. Whereas one solution was specifically optimized for freezing EDTA-blood samples, two thawing solutions used in succession were found to maximize recovery and ensure normal morphology. Having developed what appeared to be effective freeze-thaw reagents and simple cell processing methods, we proceeded to experiments that focused on whether or not they could be applied to blood samples without interfering with reliable estimations of Pig-a mutant cell frequencies.
Study1: Litron Figure 1 shows Pig-a data associated with never-frozen blood samples, and samples stored frozen for 0.5, 1, and 3 months. Whereas two-way ANOVA results highlight the obvious treatment effect on RET CD59-(p < 0.0001), they showed no evidence of a storage or treatment x storage interaction effect (p = 0.2349 and 0.9598, respectively). The same was true for RBC CD59-, where effect of Environmental and Molecular Mutagenesis. DOI 10.1002/em treatment, storage, and treatment x storage interaction produced p-values <0.0001, 0.2056, and 0.4647, respectively.
Study 2: iuvo-Litron
Data associated with an iuvo-Litron collaborative ENU study covered a wide range of RET CD59-and RBC CD59-frequencies owing to the several dose levels utilized in this experiment. Matched-pair data from fresh samples from the female rats as well as those frozen and stored by iuvo personnel until shipment occurred 1 month later are presented in Figure 2 . High R 2 values indicate strong correlations between the measurements, whereas Bland-Altman analyses provide evidence of good agreement and low bias. Note that these and other Bland-Altman plots presented herein graph the absolute difference between frozen and fresh samples. Thus, even the most divergent Y-axis value, 22.1 RET CD59-× 10
, corresponds to a relatively modest 9.9% difference between paired measurements (223.7 RET CD59-× 10 −6 vs. 245.8 RET CD59-× 10
−6
). A second set of frozen blood samples were shipped from iuvo to Litron on dry ice at the 6-month time point, and these samples were stored for an additional 1 month at −80 C before Pig-a analysis occurred. At this later time point, each of the male and female rat blood samples were evaluated (Fig. 3) . Again, very high correlation coefficients were observed for each of the three endpoints, and good agreement with low bias was achieved.
Study 3: Covance
Covance personnel were responsible for all aspects of the carboplatin Pig-a study. Thus, beyond the in-life phase, Covance personnel also froze, stored, thawed, and analyzed blood samples for RET , RBC , and RET frequencies. Whereas the ENU exposures provided a large dynamic range of mutant cell frequencies, carboplatin treatment resulted in a relatively modest increase in RET CD59-and RBC CD59-
. None the less, as shown by Figure 4 , high correlations, good agreement, and low bias were observed. There was one exceptional sample that is denoted by the grey marker that appears in Figure 4 (upper right panel) and that was omitted from the R 2 and Bland-Altman %RET analyses. Whereas the erythrocyte recoveries for each of the other samples was estimated to be on the order of ≥80% as we have come to expect, for unknown reason(s) this one sample provided less than 50% recovery. This likely explains the unusually high %RET value observed in this one frozen-thawed specimen and perhaps provides rationale for requiring some threshold level of recovery for a sample to be considered valid. Even so, it is interesting to note that low recovery for this one sample did not affect RET CD59-and RBC CD59-frequencies, as they were in Environmental and Molecular Mutagenesis. DOI 10.1002/em close agreement with values generated from fresh blood analyses.
DISCUSSION
Other erythrocyte freezing/thawing strategies have been described, including those that have been adapted for low blood sample volumes similar to those used for the Pig-a assay. Examples include droplet freezing with polyvinylpyrrolidone or sucrose plus dextrose in liquid nitrogen, and a glycerol-based method described by Schmid and colleagues (Reid and Ellisor, 1974; Schmid et al., 2011) . However, these various approaches either require specialized equipment, extensive cell washing, or other tedious blood processing steps. The method described herein may be advantageous to laboratories that do not routinely perform blood bankingcentric work, for example genetic toxicology laboratories, in that it accommodates simpler cell processing while providing similarly high erythrocyte recoveries.
The results of inter-laboratory testing presented herein clearly indicate that anticoagulated whole blood samples can be transferred to a freezing solution and stored for extended periods of time before Pig-a analyses are performed. This new capability solves certain obvious, but none the less important logistical considerations. First, scheduling of adequately trained personnel has been crucial, and this method provides increased flexibility. Second, unforeseen obstacles such as equipment failures have not been readily tolerated, thus the ability to store frozen samples represents a viable fallback option. Third, frozen specimens represent a good source of cells that are ideal for training new personnel, without the need for additional animals and treatments.
Beyond improving logistics, the ability to freeze samples for later Pig-a analyses also has several experimental design implications that further enhance the 3Rs-friendly nature of the assay. Whereas Pig-a studies have often involved the collection of serial blood samples and acquisition of longitudinal mutation frequencies, by necessity the data have been collected on separate days, using different working labeling/staining solutions, etc. A case can be made that for some study designs it would be more ideal to acquire longitudinal data for any one rodent on the same day, using the same reagents. Second, without a long-term storage option, the decision to collect Pig-a data has required advanced planning, with blood samples collected from appropriately designed studies (e.g., 28-day repeat-dose toxicity studies). However, when conducting such prospective experiments, it is not always apparent to what extent Pig-a data will be needed or useful. Rather, there are instances when investigating the toxicity profile, the need to assess a compound's potential to cause gene mutation in vivo becomes clearer at later points. For instance, it may become important to consider whether mutagenesis is playing a role when pre-neoplastic lesions and/or other indications of tumorigenicity are observed in later studies that utilize longer exposure periods. In some of these situations, it may be more strategic and 3Rs-friendly to utilize blood samples saved from an earlier study as opposed to initiating a new experiment requiring additional animals. Finally, the ability to store blood samples from genotoxicantexposed rats provides a means to generate analytical control samples, obviating the need for a concurrent group of positive control rats. Beyond representing an animal reduction opportunity, it allows one to compare new study results from previous analyses on the very same samples, thereby serving a useful quality control function.
Additional work with this system will be directed at evaluating rat blood samples that have been stored frozen for a longer period of time, testing the applicability of the method to blood of other species, and acquiring additional inter-laboratory results to ensure good transferability.
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